Skip to content
Discover J&J
Medicines & therapies
Medical devices & technology
Discover J&J
Medicines & therapies
Medical devices & technology
Media
Contact
locationPlaceholder
Choose your country or region
Global
Global
English
North America
Canada
English
Français
United States
English
Asia Pacific
Asia Pacific (Regional)
English
Australia
English
China
中文
Hong Kong
English
中文
Japan
日本
Korea
한국어
New Zealand
English
Europe, Middle East & Africa (EMEA)
EMEA (Regional)
English
Middle East - Africa
الشرق الأوسط و أفريقيا (عربي)
Austria
Deutsch
Belgium
English
Français
Netherlands
Bulgaria
БЪЛГАРСКИ
Croatia
Hrvatski
Czech Republic
čeština
Denmark
Dansk
Estonia
English
Finland
Suomi
France
Français
Germany
Deutsch
Greece
ΕΛΛΗΝΙΚΑ
Hungary
Magyar
Ireland
English
Israel
עברית
Italy
Italiano
Latvia
English
Lithuania
English
Netherlands
Netherlands
Norway
Norsk
Poland
Polski
Portugal
Português
Romania
Română
Russia
Pусский
Serbia
Srpski
Slovakia
Slovenčina
Slovenia
Slovenščina
South Africa
English
Spain
Español
Switzerland
Français
Deutsch
Sweden
Svensk
Turkey
Türkçe
United Kingdom
English
Latin America
Latin America (Regional)
Español
Argentina
Español
Bolivia
Español
Brazil
Português
Central America and the Caribbean
Español
Chile
Español
Colombia
Español
Ecuador
Español
Mexico
Español
Paraguay
Español
Peru
Español
Uruguay
Español
Healthcare areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Products
Clinical trials
Pipeline
Patient resources
Innovative Medicine
healthcare areas
Menu
Healthcare areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Products
Clinical trials
Pipeline
Patient resources
Media
Contact
Show Search
Search Query
Submit Search
Clear
Dictate search request
Search Results
No Results
Recently Viewed
Listening...
Sorry, I don't understand. Please try again
Innovative Medicine
/
Newsroom
Newsroom
The latest news from Johnson & Johnson Innovative Medicine.
Press releases
Search Query
Submit Search
Clear
Dictate search request
Listening...
Sorry, I don't understand. Please try again
998 Results
Topic
All (998)
Cardiopulmonary (96)
Communicable diseases (143)
Company news (20)
Immunology (173)
Neuroscience (62)
Oncology (320)
Sub areas
All (998)
Autoantibody (82)
Gastroenterology (51)
Immunodermatology (35)
Maternal-fetal immunology (6)
Rare autoantibody (10)
Respiratory (3)
Rheumatic diseases (67)
Rheumatology (67)
998 results
Filters
Topic
All (998)
Cardiopulmonary (96)
Communicable diseases (143)
Company news (20)
Immunology (173)
Neuroscience (62)
Oncology (320)
Sub areas
All (998)
Autoantibody (82)
Gastroenterology (51)
Immunodermatology (35)
Maternal-fetal immunology (6)
Rare autoantibody (10)
Respiratory (3)
Rheumatic diseases (67)
Rheumatology (67)
Innovative Medicine
September 10, 2024
Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)
Pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous RYBREVANT®, a three-fold reduction from 67.4 percent historically seen with standard IRR management
Read more
Innovative Medicine
September 8, 2024
RYBREVANT ® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapyfree RYBREVANT® plus LAZCLUZE™ regimen compared to osimertinib monotherapy as firstline therapy Results from an interim analysis featured in late-breaker oral presentation at WCLC
Read more
Innovative Medicine
August 29, 2024
Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis
Marks first FDA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and reduce levels of autoantibodies Filing based on the Phase 3 Vivacity-MG3 program, the first-and-only study results in the class demonstrating sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+
Read more
Innovative Medicine
August 27, 2024
European Commission approves RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer after failure of prior therapy
Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, have until now faced a poor prognosis and limited treatment options after disease progression on an EGFR TKI1,2,3,4 Amivantamab in combination with chemotherapy is the first treatment regimen to show significant improvement in progression-free survival compared to chemotherapy alone in this patient population5
Read more
Innovative Medicine
August 27, 2024
Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress
Four RYBREVANT® (amivantamab-vmjw) studies feature compelling new findings in lung and colorectal cancers New TAR-200 data reveal the potential of organ-sparing therapy for the treatment of bladder cancer
Read more
Innovative Medicine
August 23, 2024
European Commission approves BALVERSA®▼ (erdafitinib) for adult patients with unresectable or metastatic urothelial carcinoma
First pan FGFR kinase inhibitor to be approved in the European Economic Area, for adults with unresectable or metastatic urothelial carcinoma and susceptible FGFR3 alterations Approval based on THOR results, showing 36 percent reduction in risk of death with erdafitinib versus chemotherapy1
Read more
Load More